Cargando…

Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine

This randomized phase II study investigated the immunological efficacy of herbal medicines (HM) using Hochu‐ekki‐to and Keishi‐bukuryo‐gan in combination with personalized peptide vaccination (PPV) for castration‐resistant prostate cancer (CRPC). Seventy patients with CRPC were assigned to two arms;...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koga, Noriko, Moriya, Fukuko, Waki, Kayoko, Yamada, Akira, Itoh, Kyogo, Noguchi, Masanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715291/ https://www.ncbi.nlm.nih.gov/pubmed/28898532 http://dx.doi.org/10.1111/cas.13397

Ejemplares similares

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
por: Noguchi, Masanori, et al.
Publicado: (2013)

Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers
por: Noguchi, Masanori, et al.
Publicado: (2018)

A case of primary mucosa-associated lymphoid tissue lymphoma of the prostate
por: Koga, Noriko, et al.
Publicado: (2009)

Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy
por: Kawano, Kouichiro, et al.
Publicado: (2015)

Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer
por: Waki, Kayoko, et al.
Publicado: (2017)

Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
por: Suekane, Shigetaka, et al.
Publicado: (2017)

Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines
por: Saku, Shuko, et al.
Publicado: (2021)

Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11(+) or ‐A33(+) allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2017)

Identification of novel Lck‐derived T helper epitope long peptides applicable for HLA‐A2(+) cancer patients as cancer vaccine
por: Matsueda, Satoko, et al.
Publicado: (2015)

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients
por: Yutani, Shigeru, et al.
Publicado: (2015)

Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer
por: Muroya, Daisuke, et al.
Publicado: (2016)

Blockade of high mobility group box 1 augments antitumor T‐cell response induced by peptide vaccination as a co‐adjuvant
por: Waki, Kayoko, et al.
Publicado: (2016)

Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients
por: Suekane, Shigetaka, et al.
Publicado: (2020)

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2016)

Personalized peptide vaccination for advanced colorectal cancer
por: Sasada, Tetsuro, et al.
Publicado: (2015)

Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer
por: Uchino, Yoshihiro, et al.
Publicado: (2021)

PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
por: Waki, Kayoko, et al.
Publicado: (2014)

A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel
por: Noguchi, Masanori, et al.
Publicado: (2021)

Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
por: Noguchi, Masanori, et al.
Publicado: (2020)

CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine‐treated ovarian cancer patients
por: Waki, Kayoko, et al.
Publicado: (2020)

Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
por: Yutani, Shigeru, et al.
Publicado: (2017)

Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine
por: Yutani, Shigeru, et al.
Publicado: (2013)

Association of haptoglobin genetic polymorphism with overall survival in advanced castration-resistant prostate cancer patients with personalized peptide vaccination
por: Komatsu, Nobukazu, et al.
Publicado: (2013)

Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer
por: Shirahama, Takahisa, et al.
Publicado: (2017)

Reduced expression of erythropoietin-producing hepatocyte B6 receptor tyrosine kinase in prostate cancer
por: MOHAMED, ELNISR RASHED, et al.
Publicado: (2015)

Suppression of high mobility group box 1 in B16F10 tumor does not inhibit the induction of neoantigen‐specific T cells
por: Waki, Kayoko, et al.
Publicado: (2022)

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients
por: Takahashi, Ryuji, et al.
Publicado: (2014)

Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase
por: Matsueda, Satoko, et al.
Publicado: (2018)

Liver immunology and herbal treatment
por: Balaban, Yasemin H, et al.
Publicado: (2017)

Prostate cancer: Therapeutic prospect with herbal medicine
por: Ghosh, Suvranil, et al.
Publicado: (2021)

Chinese herbal medicines and nutraceuticals inhibit Pseudomonas aeruginosa biofilm formation
por: Hayashi, Minami, et al.
Publicado: (2021)

Early phase II study of mixed 19‐peptide vaccine monotherapy for refractory triple‐negative breast cancer
por: Toh, Uhi, et al.
Publicado: (2020)

Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine
por: Wang, Zhijun, et al.
Publicado: (2016)

Mesenteric Phlebosclerosis Associated with Herbal Medicine
por: Kubo, Kimitoshi, et al.
Publicado: (2020)

Interaction between Pirenzepine and Ninjinto, a Traditional Japanese Herbal Medicine, on the Plasma Gut-Regulated Peptide Levels in Humans
por: Sato, Yuhki, et al.
Publicado: (2013)

High-Throughput Immunological Analysis of Dictamni Cortex: Implication in the Quality Control of Herbal Medicine
por: Tsang, Miranda Sin-Man, et al.
Publicado: (2019)

Mouse Homologue of the Human SART3 Gene Encoding Tumor‐rejection Antigen
por: Harada, Kenji, et al.
Publicado: (2000)

Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients
por: Takahashi, Ryuji, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nptf2178jg4nbrq1bu0ucpeg2f